New Teladongo merger details. Pear's acquisitive study strategy.

Issue 068

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about Amwell's IPO filing and the possible longterm repercussions of Amazon's move into voice biomarkers via its first wearable device, Halo. Here's what's happening this week:

Teladoc-Livongo revealed more information about their multi-billion dollar merger in a lengthy government

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

New Teladongo merger details. Pear’s acquisitive study strategy.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New Teladongo merger details. Pear’s acquisitive study strategy.

Welcome to E&O.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.